Sensei Biotherapeutics, Inc. (SNSE)

US — Healthcare Sector
Peers: LABP  VOR  EVAX  DBTX  NEXI 

Automate Your Wheel Strategy on SNSE

With Tiblio's Option Bot, you can configure your own wheel strategy including SNSE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol SNSE
  • Rev/Share 0.0
  • Book/Share 1.2697
  • PB 0.2434
  • Debt/Equity 0.1003
  • CurrentRatio 6.8239
  • ROIC -0.8853

 

  • MktCap 7789303.0
  • FreeCF/Share -0.9629
  • PFCF -0.3211
  • PE -0.2682
  • Debt/Assets 0.0838
  • DivYield 0
  • ROE -0.6898

 

  • Rating
  • Score
  • Recommendation
  • P/E Score
  • DCF Score
  • P/B Score
  • D/E Score

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress
SNSE
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral

- Favorable clinical data in PD-(L)1 resistant patients - - Dose expansion enrollment complete with full data expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the first quarter 2025, and provided corporate updates. “This was a breakthrough quarter for Sensei,” said John Celebi, President and CEO.

Read More
image for news Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress

About Sensei Biotherapeutics, Inc. (SNSE)

  • IPO Date 2021-02-04
  • Website https://www.senseibio.com
  • Industry Biotechnology
  • CEO Mr. John K. Celebi M.B.A.
  • Employees 14
Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.